Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 526

1.

Tuberculosis series.

Silva DR, Mello FCQ, Kritski A, Dalcolmo M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):71-72. doi: 10.1590/s1806-37562018000020001. Portuguese, English. No abstract available.

2.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Portuguese, English.

3.

Limiting consumption in tuberculosis: current concepts in anti-tuberculosis treatment in the critically ill patient.

Mer M, Zumla A, Dünser MW.

Intensive Care Med. 2018 May 11. doi: 10.1007/s00134-018-5161-5. [Epub ahead of print] No abstract available.

PMID:
29752523
4.

Mitigating the risks of global spread of Lassa fever at the 2018 Hajj pilgrimage.

Gautret P, Okolo S, Elachola H, Zumla A, Memish ZA.

Travel Med Infect Dis. 2018 May - Jun;23:99-100. doi: 10.1016/j.tmaid.2018.04.016. Epub 2018 Apr 27. No abstract available.

PMID:
29709659
5.

Global spread of antibiotic-resistant bacteria and mass-gathering religious events.

Zumla A, Azhar EI, Hui DS, Shafi S, Petersen E, Memish ZA.

Lancet Infect Dis. 2018 May;18(5):488-490. doi: 10.1016/S1473-3099(18)30242-1. No abstract available.

PMID:
29695351
6.

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.

Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A.

Lancet Infect Dis. 2018 Apr 18. pii: S1473-3099(18)30127-0. doi: 10.1016/S1473-3099(18)30127-0. [Epub ahead of print] Review.

PMID:
29680581
7.

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.

Floyd K, Glaziou P, Zumla A, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Review.

PMID:
29595511
8.

Tuberculosis research and development: seeding the future.

Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):242-244. doi: 10.1016/S2213-2600(18)30050-X. No abstract available.

PMID:
29595503
9.

B cells or T cells in TB: a continuing conundrum.

Maeurer M, Rao M, Zumla A.

Lancet Respir Med. 2018 Apr;6(4):237-238. doi: 10.1016/S2213-2600(18)30080-8. No abstract available.

PMID:
29595500
10.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30110-5. doi: 10.1016/S1473-3099(18)30110-5. [Epub ahead of print] Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
11.

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.

Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A.

Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111-7. doi: 10.1016/S1473-3099(18)30111-7. [Epub ahead of print] Review.

PMID:
29580818
12.

Concrete action now: UN High-Level Meeting on Tuberculosis.

Herbert N, Sharma V, Masham BS, Sheehan BS, Hauser J, Zumla A.

Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30171-3. doi: 10.1016/S1473-3099(18)30171-3. [Epub ahead of print] No abstract available.

PMID:
29580817
13.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

14.

The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control.

Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M.

J Crit Care. 2018 Jun;45:184-196. doi: 10.1016/j.jcrc.2018.03.015. Epub 2018 Mar 13. Review.

PMID:
29571116
15.

Accelerating the development of therapeutic strategies for drug-resistant tuberculosis.

Vjecha MJ, Tiberi S, Zumla A.

Nat Rev Drug Discov. 2018 Mar 23. doi: 10.1038/nrd.2018.28. [Epub ahead of print]

PMID:
29567994
16.

Urgent need for multi-site controlled trials for CMV pneumonia treatment in African children.

Tembo J, Moraleda C, Rojo P, Zumla A, Bates M.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):469-470. doi: 10.5588/ijtld.17.0847. No abstract available.

PMID:
29563003
17.
18.

Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C?

Ippolito G, Zumla A, Lanini S.

Clin Microbiol Infect. 2018 Apr;24(4):328-331. doi: 10.1016/j.cmi.2018.01.001. Epub 2018 Jan 8. No abstract available.

PMID:
29326009
19.

Reply to Reisler et al.

Lanini S, Portella G, Vairo F, Di Caro A, Kobinger G, Zumla A, Ippolito G.

Clin Infect Dis. 2018 Apr 17;66(9):1480-1481. doi: 10.1093/cid/cix1026. No abstract available.

PMID:
29272344
20.

Ending the Global Tuberculosis Epidemic by 2030 - The Moscow Declaration and achieving a Major Translational Change in Delivery of TB Healthcare.

Petersen E, Blumberg L, Wilson ME, Zumla A.

Int J Infect Dis. 2017 Dec;65:156-158. doi: 10.1016/j.ijid.2017.11.029. Epub 2017 Dec 2. No abstract available.

Supplemental Content

Support Center